Mast cell proteases: physiological tools to study functional significance of high density lipoproteins in the initiation of reverse cholesterol transport

Atherosclerosis
Miriam Lee-Rueckert, Petri T Kovanen

Abstract

The extracellular fluid of the intima is rich in lipid-poor species of high density lipoproteins (HDL) that promote efficient efflux of cholesterol from macrophages. Yet, during atherogenesis, cholesterol accumulates in macrophages, and foam cells are formed. We have studied proteolytic modification of HDL by mast cell proteases as a potential mechanism of reduced cholesterol efflux from foam cells. Mast cells are present in human atherosclerotic lesions and, when activated, they expel cytoplasmic granules that are filled with heparin proteoglycans and two neutral proteases, chymase and tryptase. Both proteases were found to specifically deplete in vitro the apoA-I-containing prebeta-migrating HDL (prebeta-HDL) and other lipid-poor HDL particles that contain only apoA-IV or apoE. These losses led to inhibition of the high-affinity component of cholesterol efflux from macrophage foam cells facilitated by the ATP-binding cassette transporter A1 (ABCA1). In contrast, the diffusional component of efflux promoted by alpha-HDL particles was not changed after proteolysis. Mast cell proteases are providing new insights into the role of extracellular proteolysis of HDL as an inhibiting principle of the initial steps of reverse cholester...Continue Reading

References

Nov 1, 1992·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·M LeeP T Kovanen
Jan 1, 1990·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·S T KunitakeJ P Kane
Apr 15, 1988·Biochimica Et Biophysica Acta·D W Garber, J B Marsh
Oct 1, 1994·The Journal of Clinical Investigation·A J MendezJ F Oram
Mar 1, 1994·Proceedings of the National Academy of Sciences of the United States of America·Y HuangG Assmann
Oct 1, 1996·Current Opinion in Lipidology·A von Eckardstein
Jan 1, 1996·International Journal of Clinical & Laboratory Research·N GhalimJ C Fruchart
Dec 5, 1998·Biochimica Et Biophysica Acta·K A LindstedtP T Kovanen
Jan 14, 1999·The New England Journal of Medicine·R Ross
Apr 8, 1999·Progress in Lipid Research·A Jonas
Jun 22, 1999·The New England Journal of Medicine·G D Sloop
Sep 1, 1999·Proceedings of the National Academy of Sciences of the United States of America·S M HammadW S Argraves
Sep 17, 1999·Atherosclerosis·K A RyeP J Barter
Mar 10, 2000·Biochimica Et Biophysica Acta·C P SommerhoffH Fritz
Jul 14, 2000·The Journal of Biological Chemistry·A E BortnickO L Francone
Jul 25, 2000·Molecular Medicine Today·J L KelleyG Krishnaswamy
Sep 9, 2000·Arteriosclerosis, Thrombosis, and Vascular Biology·M N NanjeeN E Miller
Nov 4, 2000·Biochemical and Biophysical Research Communications·L Lindstedt, P T Kovanen
Dec 16, 2000·Arteriosclerosis, Thrombosis, and Vascular Biology·B F AsztalosE J Schaefer
Jan 9, 2001·Arteriosclerosis, Thrombosis, and Vascular Biology·K L OlinA Chait
Apr 20, 2001·The Journal of Biological Chemistry·N WangA R Tall
Sep 5, 2001·Frontiers in Bioscience : a Journal and Virtual Library·G KrishnaswamyD S Chi
Dec 4, 2001·Biochimica Et Biophysica Acta·C J Fielding, P E Fielding
Aug 15, 2002·Cardiovascular Research·Yoshinari UeharaKeijiro Saku
Dec 17, 2002·Arteriosclerosis, Thrombosis, and Vascular Biology·Miriam LeePetri T Kovanen

❮ Previous
Next ❯

Citations

Apr 14, 2009·Current Atherosclerosis Reports·Petri T Kovanen
Oct 1, 2008·Nature Reviews. Immunology·Christian WeberPeter Libby
Sep 2, 2011·Current Opinion in Lipidology·Miriam Lee-Rueckert, Petri T Kovanen
Jan 14, 2012·Endocrine Reviews·Jia-Ming Xu, Guo-Ping Shi
Feb 8, 2008·Clinical Chemistry and Laboratory Medicine : CCLM·Miriam Lee-RueckertPetri T Kovanen
Aug 21, 2012·Trends in Cardiovascular Medicine·Yi Wang, Guo-Ping Shi
Sep 21, 2007·Journal of Interventional Cardiology·Nicholas G KounisTheoharis C Theoharides
May 15, 2007·Immunological Reviews·Petri T Kovanen
Sep 5, 2015·Current Opinion in Lipidology·Miriam Lee-Rueckert, Petri T Kovanen
Feb 16, 2011·Clinical Science·Charlotte L WellerJonathan R Lamb
Jan 22, 2013·Pharmacology & Therapeutics·Simon KennedyPasquale Maffia
Feb 13, 2016·Fish & Shellfish Immunology·B S DezfuliL Giari
Aug 19, 2007·Journal of Lipid Research·Márcia Almeida LizMónica Mendes Sousa
Jan 8, 2011·Arteriosclerosis, Thrombosis, and Vascular Biology·Miriam Lee-RueckertJoan Carles Escola-Gil
May 16, 2007·Circulation·Peter Libby, Guo-Ping Shi
Apr 15, 2014·British Journal of Hospital Medicine·Zhanwen XuZhi-Qiang Liu
Oct 16, 2007·Molecular and Cellular Biochemistry·Songul Suren CastilloRefiye Yanardag
Jan 13, 2015·International Journal of Immunopathology and Pharmacology·E SpinasP Conti

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.